Loading data for EDIT — first visit, this takes a few seconds.
Editas Medicine Inc. (EDIT)
NasdaqGS: EDIT
· Real-Time Price · USD
3.11
+0.17 (5.78%)
At close: Aug 27, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
Editas Medicine Inc. (EDIT) Stock Price, Analysis & Data
5.78% (1D)
| Bid | 2.29 |
| Market Cap | 506.81M |
| Revenue (ttm) | 47.01M |
| Net Income (ttm) | -73.95M |
| 2.06 | |
| -0.66 | |
| n/a | |
| -4.38 | |
| P/B (ttm) | 4.81 |
| P/S (ttm) | 10.78 |
| Earnings Date | Nov 9, 2026 |
| Ask | 3.78 |
| Volume | 2,116,472 |
| Avg. Volume (20D) | 2,818,241 |
| Open | 2.98 |
| Previous Close | 2.94 |
| Day's Range | 2.95 - 3.25 |
| 52-Week Range | 1.66 - 4.54 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle ce...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 3, 2016
Employees 87
Stock Exchange NasdaqGS
Ticker Symbol EDIT
Website https://www.editasmedicine.com
Financial Performance
In 2025, Editas Medicine's revenue was 40.52M, an increase of 25.39% compared to the previous year's 32.31M. Earnings were -160.06M, a decrease of -32.49%.
Financial StatementsEarnings Surprise
Editas Medicine has released their quarterly earnings on Aug 5, 2026:
- Revenue of $11.89M misses estimates by $0, with 232.31% YoY growth.
- EPS of -0.15 exceeds estimates by 0.13, with 53.13% YoY growth.
Editas Medicine Inc. is scheduled to release its earnings on Nov 9, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2